Although the overall response rate among the cohort was 96.4%, this figure dropped as low as 66.7% when accounting for male gender, GT3 infection, cirrhosis, obesity, and non-response to previous therapy.
Infections have surged in Rzeszow, whose strategic location near the Ukrainian border has transformed it into a hub for the Western response to Russia’s invasion.